Department of Animal Biology, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.
Department of General Biology, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.
Toxicol Appl Pharmacol. 2023 Nov 1;478:116710. doi: 10.1016/j.taap.2023.116710. Epub 2023 Oct 5.
Finasteride and minoxidil are medicaments commonly prescribed for treating benign prostatic hyperplasia (BPA), hypertension, and/or androgenetic alopecia (AGA). The mechanism of action of finasteride is based on the interference in androgenic pathways, which may lead to fertility-related disorders in men. Minoxidil, however, can act in multiple ways, and there is no consensus that its use can adversely affect male fertility. Since finasteride and minoxidil could be risk factors for male fertility, we aimed to compare their impact on the two reproductive organs testis and epididymis of adult murine models, besides testis/epididymis-related cells, and describe the mechanism of action involved. For such, we used the PRISMA guideline. We included 31 original studies from a structured search on PubMed/MEDLINE, Scopus, and Web of Science databases. For in vivo studies, the bias analysis and the quality of the studies were assessed as described by SYRCLE (Systematic Review Centre for Laboratory Animal Experimentation). We concluded that finasteride and minoxidil act as hormone disruptors, causing oxidative stress and morphological changes mainly in the testis. Our results also revealed that finasteride treatment could be more harmful to male reproductive health because it was more associated with reproductive injuries, including damage to the epididymis, erectile dysfunction, decreased libido, and reduced semen volume. Thus, this study contributes to the global understanding of the mechanisms by which medicaments used for alopecia might lead to male reproductive disorders. We hope that our critical analysis expedites clinical research and reduces methodological bias. The registration number on the Prospero platform is CRD42022313347.
非那雄胺和米诺地尔是常用于治疗良性前列腺增生(BPA)、高血压和/或雄激素性脱发(AGA)的药物。非那雄胺的作用机制基于对雄激素途径的干扰,这可能导致男性生育相关疾病。然而,米诺地尔可以通过多种方式发挥作用,并且没有共识认为其使用会对男性生育力产生不利影响。由于非那雄胺和米诺地尔可能是男性生育力的危险因素,我们旨在比较它们对成年鼠模型睾丸和附睾这两个生殖器官、睾丸/附睾相关细胞的影响,并描述所涉及的作用机制。为此,我们使用了 PRISMA 指南。我们从 PubMed/MEDLINE、Scopus 和 Web of Science 数据库进行了结构化搜索,共纳入了 31 项原始研究。对于体内研究,我们按照 SYRCLE(实验室动物实验系统评价中心)描述的方法评估了偏倚分析和研究质量。我们得出结论,非那雄胺和米诺地尔作为激素干扰物,主要在睾丸中引起氧化应激和形态变化。我们的研究结果还表明,非那雄胺治疗可能对男性生殖健康更有害,因为它与生殖损伤的相关性更高,包括附睾损伤、勃起功能障碍、性欲降低和精液量减少。因此,这项研究有助于全面了解用于脱发的药物如何导致男性生殖紊乱的机制。我们希望我们的批判性分析能够促进临床研究并减少方法学偏见。在 Prospero 平台上的注册号为 CRD42022313347。